PDCD1 and neoplasm: Using baseline tumor mutation and gene-expression profiles, we identified mutated and copy number altered genes, and gene-sets associated with clinical benefit and high molecular sensitivity to pembrolizumab that are in agreement with a recent analysis of anti-PD1 treated cancers9,20.